1
0The paper investigate tumor-draining lymph nodes (TDLNs) and their critical role in regulating systemic anti-tumour immunity and patient prognosis. Researchers discovered that PLA2G2D, an immunosuppressive protein produced mainly by macrophages in the TDLN paracortex, curtails the early proliferation and activation of CD8+ T cells. Patients experiencing disease recurrence exhibit higher levels of these PLA2G2D-expressing myeloid cells, which create an immunosuppressive environment that hinders effective cancer control. Experiments in preclinical models demonstrate that genetic deletion or antibody-mediated inhibition of PLA2G2D significantly reduces tumor growth by boosting tumor-specific T cell responses. Furthermore, combining PLA2G2D blockade with anti-PD-1 immunotherapy produces additive or synergistic therapeutic benefits, highlighting PLA2G2D as a promising target for cancer immunotherapy.
References:
van Krimpen A, Huang J, Eterman M, et al. PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity[J]. Nature, 2026: 1-11.
